Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL - 16/08/11

Simona Soverini, DrPhD ^{a, ⁎} , Giovanni Martinelli, MD ^a, Sabrina Colarossi, PhD ^a, Alessandra Gnani, PhD ^a, Michela Rondoni, MD ^a, Fausto Castagnetti, MD ^a, Stefania Paolini, MD ^a, Gianantonio Rosti, MD ^a, Michele Baccarani, ProfMD ^a

^a Institute of Haematology and Medical Oncology “L. e A. Seràgnoli”, University of Bologna, Italy 

^* Correspondence to: Dr Simona Soverini, Institute of Haematology and Medical Oncology “L. e A. Seràgnoli”, S. Orsola-Malpighi Hospital, Via Massarenti 9, 40138 Bologna, Italy